KFS
TGTX icon

Kelly Financial Services’s TG Therapeutics TGTX Stock Holding History

Kelly Financial Services’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-200
Closed -$3.42K – 825
2023
Q4 		$3.42K Hold
200
– – ﹤0.01% 520
2023
Q3 		$1.67K Hold
200
– – ﹤0.01% 565
2023
Q2 		$4.97K Hold
200
– – ﹤0.01% 446
2023
Q1 		$3.01K Hold
200
– – ﹤0.01% 480
2022
Q4 		$2.37K Hold
200
– – ﹤0.01% 493
2022
Q3 		$1.18K Hold
200
– – ﹤0.01% 555
2022
Q2 		$850 Hold
200
– – ﹤0.01% 570
2022
Q1 		$1.9K Hold
200
– – ﹤0.01% 523
2021
Q4 		$3.8K Buy
+200
New +$5.19K ﹤0.01% 478

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Kelly Financial Services's TGTX Position: Q1 2024 in Review

Kelly Financial Services sold out of TG Therapeutics (TGTX) in Q1 2024, closing a stake of 200 shares — an estimated $3.42K sold.

Kelly Financial Services first reported a position in TGTX in Q4 2021 and held it in 9 quarters. The position peaked at $4.97K in Q2 2023. 243 funds tracked by Wall St. Rank hold TGTX as of Q1 2024.

  • Kelly Financial Services reported no remaining TG Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Kelly Financial Services sold 200 TG Therapeutics shares in Q1 2024, an estimated $3.42K.
  • Kelly Financial Services first reported a position in TG Therapeutics in Q4 2021 and held it in 9 quarters.
  • Kelly Financial Services's TG Therapeutics position peaked at $4.97K in Q2 2023.
  • 243 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2024.

Based on Kelly Financial Services's 13F filing for Q1 2024, filed 17 Jul 2024.